Eight biotech companies sold follow‑on offerings that collectively raised over $3.2 billion in a single overnight session, marking a record day for the sector’s capital markets. Most deals were upsized and included institutional demand across oncology, platforms and specialty biopharma names. The influx of secondary capital signals renewed public market appetite for biotech execution stories and late‑stage assets. The haul will fund clinical development and extend cash runways for multiple companies, while underwriting near‑term trial readouts and potential M&A or licensing activity. Sources: BioCentury financing reports and market coverage of the follow‑on transactions.